These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 31131509

  • 1. Performance evaluation of serum PIVKA-II measurement using HISCL-5000 and a method comparison of HISCL-5000, LUMIPULSE G1200, and ARCHITECT i2000.
    Ryu MR, Kang ES, Park HD.
    J Clin Lab Anal; 2019 Jul; 33(6):e22921. PubMed ID: 31131509
    [Abstract] [Full Text] [Related]

  • 2. Protein induced by vitamin K absence or antagonist-II (PIVKA-II) specifically increased in Italian hepatocellular carcinoma patients.
    Viggiani V, Palombi S, Gennarini G, D'Ettorre G, De Vito C, Angeloni A, Frati L, Anastasi E.
    Scand J Gastroenterol; 2016 Oct; 51(10):1257-62. PubMed ID: 27227515
    [Abstract] [Full Text] [Related]

  • 3. Analytical and Clinical Performance Evaluation of the Abbott Architect PIVKA Assay.
    Ko DH, Hyun J, Kim HS, Park MJ, Kim JS, Park JY, Shin DH, Cho HC.
    Ann Clin Lab Sci; 2018 Jan; 48(1):75-80. PubMed ID: 29531000
    [Abstract] [Full Text] [Related]

  • 4. Diagnostic value of serum PIVKA-II levels for BCLC early hepatocellular carcinoma and correlation with HBV DNA.
    Wu J, Xiang Z, Bai L, He L, Tan L, Hu M, Ren Y.
    Cancer Biomark; 2018 Jan; 23(2):235-242. PubMed ID: 30103302
    [Abstract] [Full Text] [Related]

  • 5. The clinical application of PIVKA-II in hepatocellular carcinoma and chronic liver diseases: A multi-center study in China.
    Ji J, Liu L, Jiang F, Wen X, Zhang Y, Li S, Lou J, Wang Y, Liu N, Guo Q, Jia Y, Gao C.
    J Clin Lab Anal; 2021 Nov; 35(11):e24013. PubMed ID: 34590755
    [Abstract] [Full Text] [Related]

  • 6. Measurement of des-gamma-carboxy prothrombin levels in hemodialysis patients positive for anti-hepatitis virus C antibody.
    Kato A, Yasuda H, Togawa A, Yamamoto T, Yonemura K, Maruyama T, Maruyama Y, Hishida A.
    Clin Nephrol; 2002 Oct; 58(4):296-300. PubMed ID: 12400845
    [Abstract] [Full Text] [Related]

  • 7. Development and evaluation of analytical performance of a fully automated chemiluminescent immunoassay for protein induced by vitamin K absence or antagonist II.
    Fujita K, Kinukawa H, Ohno K, Ito Y, Saegusa H, Yoshimura T.
    Clin Biochem; 2015 Dec; 48(18):1330-6. PubMed ID: 26210849
    [Abstract] [Full Text] [Related]

  • 8. A quantitative analytical method for PIVKA-II using multiple reaction monitoring-mass spectrometry for early diagnosis of hepatocellular carcinoma.
    Sohn A, Kim H, Yu SJ, Yoon JH, Kim Y.
    Anal Bioanal Chem; 2017 Apr; 409(11):2829-2838. PubMed ID: 28168546
    [Abstract] [Full Text] [Related]

  • 9. Diagnostic value of PIVKA-II and alpha-fetoprotein in hepatitis B virus-associated hepatocellular carcinoma.
    Seo SI, Kim HS, Kim WJ, Shin WG, Kim DJ, Kim KH, Jang MK, Lee JH, Kim JS, Kim HY, Kim DJ, Lee MS, Park CK.
    World J Gastroenterol; 2015 Apr 07; 21(13):3928-35. PubMed ID: 25852278
    [Abstract] [Full Text] [Related]

  • 10. A comparative evaluation of Golgi protein-73, fucosylated hemopexin, α-fetoprotein, and PIVKA-II in the serum of patients with chronic hepatitis, cirrhosis, and hepatocellular carcinoma.
    Morota K, Nakagawa M, Sekiya R, Hemken PM, Sokoll LJ, Elliott D, Chan DW, Dowell BL.
    Clin Chem Lab Med; 2011 Apr 07; 49(4):711-8. PubMed ID: 21231906
    [Abstract] [Full Text] [Related]

  • 11. Protein Induced by Vitamin K Absence II (PIVKA-II) as a potential serological biomarker in pancreatic cancer: a pilot study.
    Tartaglione S, Pecorella I, Zarrillo SR, Granato T, Viggiani V, Manganaro L, Marchese C, Angeloni A, Anastasi E.
    Biochem Med (Zagreb); 2019 Jun 15; 29(2):020707. PubMed ID: 31223261
    [Abstract] [Full Text] [Related]

  • 12. PIVKA-II as a Potential New Biomarker for Hepatocellular Carcinoma - A Pilot Study.
    Svobodova S, Karlikova M, Topolcan O, Pecen L, Pestova M, Kott O, Treska V, Slouka D, Kucera R.
    In Vivo; 2018 Jun 15; 32(6):1551-1554. PubMed ID: 30348715
    [Abstract] [Full Text] [Related]

  • 13. Fully validated SRM-MS-based method for absolute quantification of PIVKA-II in human serum: Clinical applications for patients with HCC.
    Sohn A, Kim H, Yeo I, Kim Y, Son M, Yu SJ, Yoon JH, Kim Y.
    J Pharm Biomed Anal; 2018 Jul 15; 156():142-146. PubMed ID: 29702392
    [Abstract] [Full Text] [Related]

  • 14. Usefulness of determining a protein induced by vitamin K absence in detection of hepatocellular carcinoma.
    Cui R, Wang B, Ding H, Shen H, Li Y, Chen X.
    Chin Med J (Engl); 2002 Jan 15; 115(1):42-5. PubMed ID: 11930656
    [Abstract] [Full Text] [Related]

  • 15. Diagnostic performance of tumor markers AFP and PIVKA-II in Chinese hepatocellular carcinoma patients.
    Huang S, Jiang F, Wang Y, Yu Y, Ren S, Wang X, Yin P, Lou J.
    Tumour Biol; 2017 Jun 15; 39(6):1010428317705763. PubMed ID: 28621228
    [Abstract] [Full Text] [Related]

  • 16. Usefulness of AFP, AFP-L3, and PIVKA-II, and their combinations in diagnosing hepatocellular carcinoma.
    Park SJ, Jang JY, Jeong SW, Cho YK, Lee SH, Kim SG, Cha SW, Kim YS, Cho YD, Kim HS, Kim BS, Park S, Bang HI.
    Medicine (Baltimore); 2017 Mar 15; 96(11):e5811. PubMed ID: 28296720
    [Abstract] [Full Text] [Related]

  • 17. A multicenter study on PIVKA reference interval of healthy population and establishment of PIVKA cutoff value for hepatocellular carcinoma diagnosis in China.
    Qin X, Tang G, Gao R, Guo Z, Liu Z, Yu S, Chen M, Tao Z, Li S, Liu M, Wang L, Hou L, Xia L, Cheng X, Han J, Qiu L.
    Int J Lab Hematol; 2017 Aug 15; 39(4):392-401. PubMed ID: 28318145
    [Abstract] [Full Text] [Related]

  • 18. Risk of hepatocellular carcinoma in HBV cirrhotic patients assessed by the combination of miR-122, AFP and PIVKA-II.
    Caviglia GP, Abate ML, Gaia S, Petrini E, Bosco C, Olivero A, Rosso C, Ciancio A, Pellicano R, Saracco GM, Rizzetto M, Smedile A.
    Panminerva Med; 2017 Dec 15; 59(4):283-289. PubMed ID: 28650134
    [Abstract] [Full Text] [Related]

  • 19. Role of serum prothrombin induced by vitamin K absence or antagonist-II in the early detection of hepatocellular carcinoma in patients with chronic hepatitis B virus infection.
    Yoon YJ, Han KH, Kim DY.
    Scand J Gastroenterol; 2009 Dec 15; 44(7):861-6. PubMed ID: 19391065
    [Abstract] [Full Text] [Related]

  • 20. Clinical evaluation of plasma abnormal prothrombin (PIVKA-II) in patients with hepatocellular carcinoma.
    Fujiyama S, Morishita T, Sagara K, Sato T, Motohara K, Matsuda I.
    Hepatogastroenterology; 1986 Oct 15; 33(5):201-5. PubMed ID: 2433199
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.